FK 973

10/01/1989 - "In the vivo experiments, FK973 and its metabolites prolonged the life of mice bearing ascitic P388 leukemia, and it potently inhibited the growth of murine B16 melanoma and Colon 38 adenocarcinoma implanted subcutaneously in mice. "
03/01/1988 - "In studies with drug-resistant P388 leukemia, FK973 was also effective against vincristine-resistant P388, moderately effective against mitomycin C (MMC)- and adriamycin-resistant P388, and partially effective against cyclophosphamide-resistant P388 cells in mice. "

07/01/1989 - "[Antitumor efficacy of FK 973 on malignant glioma cells]."
12/20/1990 - "[Antitumor activity of FK973 for malignant gliomas and its assessment for normal brain cells]."
07/01/1989 - "FK 973 showed antitumor efficacy in the meningeal gliomatosis models by RSV-M glioma cells. "
07/01/1989 - "FK 973 had cytotoxic effects against in vitro cultured human and murine glioma cells. "
11/01/1991 - "Cytotoxic effects of a new antitumor antibiotic, FK973, in malignant glioma."

01/01/1998 - "These results suggest that FK317 retains the antitumor activity of FK973 and does not induce VLS, and FK317 is a drug with high clinical potential for treating tumors in humans."
10/01/1991 - "FK973 was the most potent of the four drugs tested against the growth of the three squamous cancer cell lines derived from oral cavity. "
03/01/1988 - "The results suggest that FK973 will be a beneficial drug for the treatment of cancer."
03/01/1988 - "FK973 had cytotoxic effects against in vitro cultured human and murine tumor cells. "
03/01/1989 - "Our previous study showed that FK973 (11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11- diazatetracyclo[7.4.1.0(2,7)0(10,12)]tetradeca-2,4,6-trien-6 ,9-diyl diacetate), a novel substituted dihydrobenzoxazine, which is a derivative of the fermentation product of Streptomyces sandaensis No. 6897, had strong antitumor effects on experimental tumors in vitro and in vivo. "

10/01/1989 - "FK973 and all its deacetylated metabolites showed strong cytotoxicity on in vitro cultured murine L1210 leukemia cells, and the cytotoxicity of FK973 was the most potent. "
08/01/1990 - "In this study, the mechanism(s) by which FK973 is activated in the cytoplasm of in vitro cultured murine L1210 leukemia cells were studied using compounds that affect monoamine oxidase. "
08/01/1990 - "Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells."
03/01/1988 - "FK973 in doses of 0.032-5.6 mg/kg (i.p.) had stronger antitumor activities and higher chemotherapeutic ratio than mitomycin C against such murine ascitic tumors as P388 and L1210 leukemia, B16 melanoma, M5076 reticulum cell sarcoma of ovarian origin, Colon 26 carcinoma, Ehrlich carcinoma, and MH134 hepatoma. "

03/01/1993 - "During Phase I clinical trials, we evaluated the pharmacologic properties of FK 973 in eight adenocarcinoma patients after a 30-min i.v. infusion of doses ranging from 7 to 45mg/m2. "
10/01/1989 - "In the vivo experiments, FK973 and its metabolites prolonged the life of mice bearing ascitic P388 leukemia, and it potently inhibited the growth of murine B16 melanoma and Colon 38 adenocarcinoma implanted subcutaneously in mice. "
10/01/1991 - "FK973 (11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1, 11-diazatetracyclo [7.4.1.0.0] tetradeca-2, 4, 6-trien-6, 9-diyl diacetate), an analogue of mitomycin C (MMC), was tested against human oral squamous cancer cell lines Ca 9-22, HSC-2, HSC-3, breast adenocarcinoma cell lines MCF-7, BT-20 and breast ductal carcinoma cell line T-47D using MTT assay. "